Next-generation sequencing has revealed recurring somatic mutations in Waldenström
macroglobulinemia (WM), including MYD88 (95%-97%), CXCR4 (30%-40%), ARID1A …

With the introduction of large-scale molecular profiling methods and high-throughput
sequencing technologies, the genomic features of most lymphoid neoplasms have been …

Next-generation sequencing has revealed recurring somatic mutations in Waldenström
macroglobulinemia (WM). Commonly recurring mutations include MYD88 (95% to 97%) …

PURPOSE We report the long-term findings and final analysis of a pivotal multicenter trial of
ibrutinib monotherapy in previously treated patients with Waldenström macroglobulinemia …

Purpose Ibrutinib is active in previously treated Waldenström macroglobulinemia (WM).
MYD88 mutations (MYD88 MUT) and CXCR4 mutations (CXCR4 MUT) affect ibrutinib …

Patients with Waldenström macroglobulinemia (WM) lacking activating mutations in the
MYD88 gene (MYD88 WT) have demonstrated relatively poor outcomes to ibrutinib …

Ibrutinib is associated with response rate of 90% and median progression‐free survival
(PFS) in excess of 5 years in Waldenström macroglobulinaemia (WM) patients. CXCR4 …

MYD88 and CXCR4 mutations are common in Waldenström macroglobulinemia (WM).
Mutated CXCR4 (CXCR4Mut) impacts BTK-inhibitor response. We conducted a phase 1 trial …

Activating MYD88 mutations are present in 95% of Waldenström macroglobulinemia (WM)
patients, and trigger NF-κB through BTK and IRAK. The BTK inhibitor ibrutinib is active in …

The diagnosis of Waldenström's macroglobulinemia (WM), an IgM-associated
lymphoplasmacytic lymphoma, can be challenging due to the different forms of disease …